CGRP receptor antagonists: Design and screening

Expert Opinion on Drug Discovery

Volumn 4, Issue 12, 2009, Pages 1253-1265

  Poyner, David R ^a   Hay, Debbie L ^b   Conner, Alex C ^c  

^a ASTON UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

Cell signalling; G protein coupled receptor; Migraine; Modelling

Indexed keywords

BMS 694153; CALCITONIN GENE RELATED PEPTIDE RECEPTOR; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; CALCITONIN GENE RELATED PEPTIDE[8-37]; CALCITONIN RECEPTOR LIKE RECEPTOR; OLCEGEPANT; RECEPTOR ACTIVITY MODIFYING PROTEIN 1; TELCAGEPANT; UNCLASSIFIED DRUG;

ANALGESIA; ANGIOGENESIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG TARGETING; FLUSHING; HUMAN; LIVER FUNCTION; MIGRAINE; NEUROGENIC INFLAMMATION; NONHUMAN; OSSIFICATION; PRIORITY JOURNAL; PROTEIN STRUCTURE; REVIEW; SEPTIC SHOCK; SIDE EFFECT; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT;

EID: 73549086745     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460440903413496     Document Type: Review

References (96)

1. Poyner DR, Sexton PM, Marshall I, et al. International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol Rev 2002;54(2):233-246
2. McLatchie LM, Fraser NJ, Main MJ, et al. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 1998;393(6683):333-339
3. Recober A, Russo AF. Calcitonin gene-related peptide: an update on the biology. Curr Opin Neurol 2009;22(3):241-246
4. Wimalawansa SJ. Calcitonin gene-related peptide and its receptors: Molecular genetics, physiology, pathophysiology, and therapeutic potentials. Endocr Rev 1996;17:533-585
5. Lu JT, Son YJ, Lee J, et al. Mice lacking alpha-calcitonin gene-related peptide exhibit normal cardiovascular regulation and neuromuscular development. Mol Cell Neurosci 1999;14(2):99-120
6. Gangula PR, Zhao H, Supowit SC, et al. Increased blood pressure in alpha-calcitonin gene-related peptide/ calcitonin gene knockout mice. Hypertension 2000;35(1 Pt 2):470-475
7. Li J, Zhao H, Supowit SC, et al. Activation of the renin-angiotensin system in alpha-calcitonin gene-related peptide/calcitonin gene knockout mice. J Hypertens 2004;22(7):1345-1349
8. Kurihara H, Shindo T, Oh-Hashi Y, et al. Targeted disruption of adrenomedullin and alphaCGRP genes reveals their distinct biological roles. Hypertens Res 2003;26 Suppl:S105-8
9. Shindo T, Kurihara Y, Nishimatsu H, et al. Vascular abnormalities and elevated blood pressure in mice lacking adrenomedullin gene. Circulation 2001;104(16):1964-1971
10. Chai W, Mehrotra S, Jan Danser AH, Schoemaker RG. The role of calcitonin gene-related peptide (CGRP) in ischemic preconditioning in isolated rat hearts. Eur J Pharmacol 2006;531(1-3):246-253
11. Ohno T, Hattori Y, Komine R, et al. Roles of calcitonin gene-related peptide in maintenance of gastric mucosal integrity and in enhancement of ulcer healing and angiogenesis. Gastroenterology 2008;134(1):215-225
12. Carpenter KA, Schmidt R, von Mentzer B, et al. Turn structures in CGRP C-terminal analogues promote stable arrangements of key residue side chains. Biochemistry 2001;40(28):8317-8325
13. Lang M, De Pol S, Baldauf C, et al. Identification of the key residue of calcitonin gene related peptide (CGRP) 27-37 to obtain antagonists with picomolar affinity at the CGRP receptor. J Med Chem 2006;49(2):616-624
14. Banerjee S, Evanson J, Harris E, et al. Identification of specific calcitonin-like receptor residues important for calcitonin gene-related peptide high affinity binding. BMC Pharmacol 2006;6:9
15. Chiba T, Yamaguchi A, Yamatani T, et al. Calcitonin gene-related peptide receptor antagonist human CGRP-(8-37). Am J Physiol 1989;256(2 Pt 1):E331-5
16. Hoare SR. Mechanisms of peptide and nonpeptide ligand binding to Class B G-protein-coupled receptors. Drug Discov Today 2005;10(6):417-427
17. Lang M, Beck-Sickinger AG. Structure-activity relationship studies: methods and ligand design for G-protein coupled peptide receptors. Curr Protein Pept Sci 2006;7(4):335-353
18. Taylor CK, Smith DD, Hulce M, Abel PW. Pharmacological characterization of novel alpha-Calcitonin Gene-Related Peptide (CGRP) receptor peptide antagonists that are selective for human CGRP receptors. J Pharmacol Exp Ther 2006;319(2):749-757
19. Ashina S, Bendtsen L, Ashina M, et al. Generalized hyperalgesia in patients with chronic tension-type headache. Cephalalgia 2006;26(8):940-948
20. Bellamy JL, Cady RK, Durham PL. Salivary Levels of CGRP and VIP in Rhinosinusitis and Migraine Patients. Headache J Head Face Pain 2006;46(1):24-33
21. Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: Studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993;33:48-56
22. Lassen LH, Haderslev PA, Jacobsen VB, et al. CGRP may play a causative role in migraine. Cephalalgia 2002;22(1):54-61
23. Chiba T, Yamaguchi A, Yamatani T, et al. Calcitonin gene-related peptide receptor antagonist human CGRP-(8-37). Am J Physiol 1989;256(2 Pt 1):E331-5
24. Brain SD, Grant AD. Vascular actions of calcitonin gene-related peptide and adrenomedullin. Physiol Rev 2004;84(3):903-934
25. Mogil JS, Miermeister F, Seifert F, et al. Variable sensitivity to noxious heat is mediated by differential expression of the CGRP gene. Proc Natl Acad Sci USA 2005;102(36):12938-12943
26. Okajima K, Harada N. Regulation of inflammatory responses by sensory neurons: molecular mechanism(s) and possible therapeutic applications. Curr Med Chem 2006;13(19):2241-2251
27. Bourdu S, Dapoigny M, Chapuy E, et al. Rectal instillation of butyrate provides a novel clinically relevant model of noninflammatory colonic hypersensitivity in rats. Gastroenterology 2005;128(7):1996-2008
28. Arnalich F, Hernanz A, Jimenez M, et al. Relationship between circulating levels of calcitonin gene-related peptide, nitric oxide metabolites and hemodynamic changes in human septic shock. Regul Pept 1996;65(2):115-121
29. Arden WA, Fiscus RR, Wang X, et al. Elevations in circulating calcitonin gene-related peptide correlate with hemodynamic deterioration during endotoxic shock in pigs. Circ Shock 1994;42(3):147-153
30. Monneret G, Pachot A, Laroche B, et al. Procalcitonin and calcitonin gene-related peptide decrease LPS-induced tnf production by human circulating blood cells. Cytokine 2000;12(6):762-764
31. Wyon Y, Spetz AC, Hammar M, et al. Urinary excretion of calcitonin gene-related peptide in males with hot flushes after castration for carcinoma of the prostate. Scand J Urol Nephrol 2001;35(2):92-96
32. Wyon YA, Spetz AC, Theodorsson GE, Hammar ML. Concentrations of calcitonin gene-related peptide and neuropeptide Y in plasma increase during flushes in postmenopausal women. Menopause 2000;7(1):25-30
33. Schinke T, Liese S, Priemel M, et al. Decreased bone formation and osteopenia in mice lacking alpha-calcitonin gene-related peptide. J Bone Miner Res 2004;19(12):2049-2056
34. Wedemeyer C, Neuerburg C, Pfeiffer A, et al. Polyethylene particle-induced bone resorption in alpha-calcitonin gene-related peptide-deficient mice. J Bone Miner Res 2007;22(7):1011-1019 (Pubitemid 351339723)
35. Bowe JE, Li XF, Kinsey-Jones JS, et al. Calcitonin gene-related peptide-induced suppression of luteinizing hormone pulses in the rat: the role of endogenous opioid peptides. J Physiol 2005;566(Pt 3):921-928
36. Schorscher-Petcu A, Austin JS, Mogil JS, Quirion R. Role of Central Calcitonin Gene-Related Peptide (CGRP) in Locomotor and Anxiety- and Depression-Like Behaviors in Two Mouse Strains Exhibiting a CGRP-Dependent Difference in Thermal Pain Sensitivity. J Mol Neurosci 2009
37. Toda M, Suzuki T, Hosono K, et al. Neuronal system-dependent facilitation of tumor angiogenesis and tumor growth by calcitonin gene-related peptide. Proc Natl Acad Sci USA 2008;105(36):13550-13555
38. Dennis T, Fournier A, Cadieux A, et al. hCGRP8-37, a calcitonin gene-related peptide antagonist revealing calcitonin gene-related peptide receptor heterogeneity in brain and periphery. J Pharmacol Exp Ther 1990;254(1):123-128
39. Choksi T, Hay DL, Legon S, et al. Comparison of the expression of calcitonin receptor-like receptor (CRLR) and receptor activity modifying proteins (RAMPs) with CGRP and adrenomedullin binding in cell lines. Br J Pharmacol 2002;136(5):784
40. Christopoulos G, Perry KJ, Morfis M, et al. Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product. Mol Pharmacol 1999;56(1):235-242
41. Hay DL, Christopoulos G, Christopoulos A, et al. Pharmacological discrimination of calcitonin receptor: receptor activity-modifying protein complexes. Mol Pharmacol 2005;67(5):1655-1665
42. Hay DL, Poyner DR, Quirion R. International Union of Pharmacology. LXIX. Status of the calcitonin gene-related peptide subtype 2 receptor. Pharmacol Rev 2008;60(2):143-145
43. Fraser NJ, Wise A, Brown J, et al. The amino terminus of receptor activity modifying proteins is a critical determinant of glycosylation state and ligand binding of calcitonin receptor-like receptor. Mol Pharmacol 1999;55(6):1054-1059 (Pubitemid 29252372)
44. Heroux M, Hogue M, Lemieux S, Bouvier M. Functional Calcitonin Gene-related Peptide Receptors Are Formed by the Asymmetric Assembly of a Calcitonin Receptor-like Receptor Homo-oligomer and a Monomer of Receptor Activity-modifying Protein-1. J Biol Chem 2007;282(43):31610-31620
45. Sexton PM, Christopoulos G, Christopoulos A, et al. Procalcitonin has bioactivity at calcitonin receptor family complexes: potential mediator implications in sepsis. Crit Care Med 2008;36(5):1637-1640
46. Prado MA, Evans-Bain B, Oliver KR, Dickerson IM. The role of the CGRP-receptor component protein (RCP) in adrenomedullin receptor signal transduction. Peptides 2001;22(11):1773-1781
47. Doods H, Hallermayer G, Wu D, et al. Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br J Pharmacol 2000;129(3):420-423
48. Olesen J, Diener HC, Husstedt IW, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 2004;350(11):1104-1110
49. Rudolf K, Eberlein W, Engel W, et al. Development of human calcitonin gene-related peptide (CGRP) receptor antagonists. 1. Potent and selective small molecule CGRP antagonists. 1-[N2- [3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)- oxoquinazolin-3-yl)-1-piperidi nyl] carbonyl]-D-tyrosyl]-l-lysyl]-4-(4- pyridinyl)piperazine: the first CGRP antagonist for clinical trials in acute migraine. J Med Chem 2005;48(19):5921-5931
50. Paone DV, Shaw AW, Nguyen DN, et al. Potent, orally bioavailable calcitonin gene-related peptide receptor antagonists for the treatment of migraine: discovery of N-[(3R,6S)-6-(2,3-difluorophenyl)-2- oxo-1- (2,2,2-trifluoroethyl)azepan-3-yl]- 4- (2-oxo-2,3-dihydro-1H-imidazo[4,5-b] pyridin- 1-yl)piperidine-1-carboxamide (MK-0974). J Med Chem 2007;50(23):5564-5567
51. Roller S, Cui D, Laspina C, et al. Preclinical pharmacokinetics of MK-0974, an orally active calcitonin-gene related peptide (CGRP)-receptor antagonist, mechanism of dose dependency and species differences. Xenobiotica 2009;39(1):33-45
52. Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 2008;372(9656):2115-2123
53. Degnan AP, Chaturvedula PV, Conway CM, et al. Discovery of (R)-4-(8-fluoro-2-oxo-1,2- dihydroquinazolin-3(4H)-yl)-N-(3-(7- methyl-1H-in dazol-5-yl)-1-oxo-1-(4- (piperidin-1-yl)piperidin-1-yl)propan-2- yl)piperidi ne-1-carboxamide (BMS-694153): a potent antagonist of the human calcitonin gene-related peptide receptor for migraine with rapid and efficient intranasal exposure. J Med Chem 2008;51(16):4858-4861
54. Miller LJ. Informed development of drugs acting at family B G protein-coupled receptors. Ann NY Acad Sci 2008;1144:203-209
55. Mallee JJ, Salvatore CA, LeBourdelles B, et al. Receptor activity-modifying protein 1 determines the species selectivity of non-peptide CGRP receptor antagonists. J Biol Chem 2002;277:14294-14298
56. Hay DL, Poyner DR, Sexton PM. GPCR modulation by RAMPs. Pharmacol Ther 2006;109(1-2):173-197
57. Salvatore CA, Mallee JJ, Bell IM, et al. Identification and pharmacological characterization of domains involved in binding of CGRP receptor antagonists to the calcitonin-like receptor. Biochemistry 2006;45(6):1881-1887
58. Kusano S, Kukimoto-Niino M, Akasaka R, et al. Crystal structure of the human receptor activity-modifying protein 1 extracellular domain. Protein Sci 2008;17(11):1907-1914
59. Christopoulos A, Christopoulos G, Morfis M, et al. Novel receptor partners and function of receptor activitymodifying proteins. J Biol Chem 2003;278(5):3293-3297
60. Bouschet T, Martin S, Henley JM. Receptor-activity-modifying proteins are required for forward trafficking of the calcium-sensing receptor to the plasma membrane. J Cell Sci 2005;118(Pt 20):4709-4720
61. Sexton PM, Poyner DR, Simms J, et al. Modulating receptor function through RAMPs: can they represent drug targets in themselves? Drug Discov Today 2009;14(7-8):413-419
62. Kuwasako K, Kitamura K, Nagoshi Y, et al. Identification of the human receptor activity-modifying protein 1 domains responsible for agonist binding specificity. J Biol Chem 2003;278(25):22623-22630
63. Simms J, Hay DL, Bailey RJ, et al. Structure-function analysis of RAMP1 by alanine mutagenesis. Biochemistry 2009;48(1):198-205
64. Hay DL, Christopoulos G, Christopoulos A, Sexton PM. Determinants of 1-piperidinecarboxamide, N-[2-[[5-amino-l-[[4-(4-pyridinyl)-lpiperazinyl] carbonyl]pentyl]amino]-1- [(3,5-dibromo-4-hydroxyphenyl)methyl]- 2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2 H)- quinazolinyl) (BIBN4096BS) affinity for calcitonin gene-related peptide and amylin receptors-the role of receptor activity modifying protein 1. Mol Pharmacol 2006;70(6):1984-1991
65. Pioszak AA, Xu HE. Molecular recognition of parathyroid hormone by its G protein-coupled receptor. Proc Natl Acad Sci USA 2008;105(13):5034-5039
66. Sun C, Song D, Davis-Taber RA, et al. Solution structure and mutational analysis of pituitary adenylate cyclase-activating polypeptide binding to the extracellular domain of PAC1-RS. Proc Natl Acad Sci USA 2007;104(19):7875-7880
67. Grace CR, Perrin MH, Gulyas J, et al. Structure of the N-terminal domain of a type B1 G protein-coupled receptor in complex with a peptide ligand. Proc Natl Acad Sci USA 2007
68. Parthier C, Kleinschmidt M, Neumann P, et al. Crystal structure of the incretinbound extracellular domain of a G proteincoupled receptor. Proc Natl Acad Sci USA 2007;104(35):13942-13947
69. Parthier C, Reedtz-Runge S, Rudolph R, Stubbs MT. Passing the baton in class B GPCRs: peptide hormone activation via helix induction? Trends Biochem Sci 2009;34(6):303-310
70. Ittner LM, Koller D, Muff R, et al. The N-terminal extracellular domain 23-60 of the calcitonin receptor-like receptor in chimeras with the parathyroid hormone receptor mediates association with receptor activity-modifying protein 1. Biochemistry 2005;44(15):5749-5754
71. Salvatore CA, Mallee JJ, Bell IM, et al. Identification and pharmacological characterization of domains involved in binding of CGRP receptor antagonists to the calcitonin-like receptor. Biochemistry 2006;45(6):1881-1887
72. Aiyar N, Daines RA, Disa J, et al. Pharmacology of SB-273779, a nonpeptide calcitonin gene-related peptide 1 receptor antagonist. J Pharmacol Exp Ther 2001;296(3):768-775
73. Conner AC, Simms J, Howitt SG, et al. Multiple residues within the second extracellular loop of the CL receptor are required for receptor activation by CGRP pA2. Online 2005;3:99
74. Edvinsson L, Nilsson E, Jansen-Olesen I. Inhibitory effect of BIBN4096BS, CGRP (8-37), a CGRP antibody and an RNA-Spiegelmer on CGRP induced vasodilatation in the perfused and non-perfused rat middle cerebral artery. Br J Pharmacol 2007;150(5):633-640
75. Vater A, Jarosch F, Buchner K, Klussmann S. Short bioactive Spiegelmers to migraine-associated calcitonin gene-related peptide rapidly identified by a novel approach: tailored-SELEX. Nucleic Acids Res 2003;31(21):e130
76. Roldos V, Martin-Santamaria S, Julian M, et al. Small-molecule negative modulators of adrenomedullin: design, synthesis, and 3D-QSAR study. ChemMedChem 2008;3(9):1345-1355
77. Zhang XP, Hintze TH. cAMP signal transduction induces eNOS activation by promoting PKB phosphorylation. Am J Physiol Heart Circ Physiol 2006;290(6):H2376-84
78. Wellman GC, Quayle JM, Standen NB. ATP-sensitive K+ channel activation by calcitonin gene-related peptide and protein kinase A in pig coronary arterial smooth muscle. J Physiol 1998;507(Pt 1):117-129
79. Simonetti M, Giniatullin R, Fabbretti E. Mechanisms mediating the enhanced gene transcription of P2X3 receptor by calcitonin gene-related peptide in trigeminal sensory neurons. J Biol Chem 2008;283(27):18743-18752
80. + signaling pathways. Mol Cell Biochem 1999;197(1-2):179-185
81. Burns DM, Stehno-Bittel L, Kawase T. Calcitonin gene-related peptide elevates calcium and polarizes membrane potential in MG-63 cells by both cAMPindependent and -dependent mechanisms. Am J Physiol Cell Physiol 2004;287(2):C457-67
82. Dong YL, Green KE, Vegiragu S, et al. Evidence for decreased calcitonin gene-related peptide (CGRP) receptors and compromised responsiveness to CGRP of fetoplacental vessels in preeclamptic pregnancies. J Clin Endocrinol Metab 2005;90(4):2336-2343
83. + concentrations but not cyclic AMP formation in CGRP receptor-positive osteosarcoma cells (OHS-4). Cytokine 1999:200-207
84. + in rat chromaffin cells in vitro. J Neurosci 1999;19(8):2945-2953
85. +-decrease. J Membr Biol 2002;189(3):225-236
86. + responses in cultured astrocytes and in Bergmann glial cells from cerebellar slices. Eur J Neurosci 2008;28(11):2213-2220
87. Vause CV, Durham PL. CGRP stimulation of iNOS and NO release from trigeminal ganglion glial cells involves mitogen-activated protein kinase pathways. J Neurochem 2009;110(3):811-821
88. Schaeffer C, Vandroux D, Thomassin L, et al. Calcitonin gene-related peptide partly protects cultured smooth muscle cells from apoptosis induced by an oxidative stress via activation of ERK1/2 MAPK. Biochim Biophys Acta 2003;1643(1-3):65-73
89. Yu XJ, Li CY, Wang KY, Dai HY. Calcitonin gene-related peptide regulates the expression of vascular endothelial growth factor in human HaCaT keratinocytes by activation of ERK1/2 MAPK. Regul Pept 2006;137(3):134-139
90. Conner M, Hicks MR, Dafforn T, et al. Functional and biophysical analysis of the C-terminus of the CGRP-receptor; a family B GPCR. Biochemistry 2008;47(32):8434-8444
91. Disa J, Dang K, Tan KB, Aiyar N. Interaction of adrenomedullin with calcitonin receptor in cultured human breast cancer cells, T 47D. Peptides 1998;19(2):247-251 (Pubitemid 28097924)
92. Hilairet S, Belanger C, Bertrand J, et al. Agonist-promoted internalization of a ternary complex between calcitonin receptor-like receptor, receptor activity-modifying protein 1 (RAMP1), and beta-arrestin. J Biol Chem 2001;276:42182-42190
93. Schindler M, Doods HN. Binding properties of the novel, non-peptide CGRP receptor antagonist radioligand, [3H]BIBN4096BS. Eur J Pharmacol 2002;442(3):187-193
94. Salvatore CA, Hershey JC, Corcoran HA, et al. Pharmacological Characterization of MK-0974 [N-[(3R,6S)-6-(2,3- Difluorophenyl)-2-oxo-1-(2,2,2- trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3- dihydro-1H-imidazo[4,5-b]pyridin-1-yl) piperidine-1-carboxamide], a Potent and Orally Active Calcitonin Gene-Related Peptide Receptor Antagonist for the Treatment of Migraine. J Pharmacol Exp Ther 2008;324(2):416-421
95. Robinson SD, Aitken JF, Bailey RJ, et al. Novel peptide antagonists of adrenomedullin and calcitonin generelated peptide receptors; identification, pharmacological characterization and interactions with position 74 in RAMP1/3. J Pharmacol Exp Ther 2009
96. Runge S, Thogersen H, Madsen K, et al. Crystal structure of the ligand-bound glucagon-like peptide-1 receptor extracellular domain. J Biol Chem 2008;283(17):11340-11347